Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Detailed Action
The Amendments and Remarks filed 1/12/26 in response to the Office Action of 9/11/25 are acknowledged and have been entered.
Claims 1-6 and 8-20 are pending.
Claims 2, 4, 6, 8, 11, 12, 16-18, and 20 have been amended by Applicant.
Claims 1-6 and 8-20 are currently under examination.
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
This Office Action contains a New Rejection necessitated by New Considerations.
Objections Withdrawn
All previous objections are withdrawn.
Rejections Withdrawn
All previous rejections are withdrawn.
New Rejections
Claim Rejections - 35 USC § 102
Claim(s) 1-5 and 14-20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Barakat et al (Cancer Letters, 2016, 375: 152-161), as evidenced by the instant specification.
Barakat et al teaches treating a subject having PC3 prostate cancer comprising administering the proteasome inhibitor bortezomib to the subject (Fig. 5, in particular).
Barakat et al does not mention ATAD1 or PTEN. However, as evidenced by [0076] on page 18 of the instant specification, PC3 prostate cancer cells are PTEN-null and are hemizygous for ATAD1 (the cancer has a non-functional ATAD1 gene where a portion or all of an ATAD1 gene is deleted).
As defined by instant claim 14, such a method appears to be equivalent to a method of increasing apoptosis because the method of Barakat et al administers recited reagents to subjects comprising a non-functional ATAD1 gene.
Allowable Subject Matter
Claims 6 and 8-13 are allowed.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN E AEDER whose telephone number is (571)272-8787. The examiner can normally be reached M-F 9am-6pm ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SEAN E AEDER/Primary Examiner, Art Unit 1642
Prosecution Insights